Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewPep2m, myristoylated
说明： Peptide inhibitor of GluA2 subunit binding to NSF; myristoylated form of pep2m (Cat. No. 1595).
别名： myr-pep2m
生物活性 for Pep2m, myristoylated
Pep2m, myristoylated is a cell-permeable, myristoylated form of pep2m (Cat. No. 1595). Peptide inhibitor of the interaction between the C-terminus of the GluA2 (AMPA receptor) subunit and N-ethylmaleimide-sensitive fusion protein (NSF), a protein that regulates AMPA receptor function. Reduces postsynaptic currents in CA1 neurons, AMPA-mediated currents in cultured hippocampal neurons and AMPA receptor surface expression.
技术数据 for Pep2m, myristoylated
| 分子量 | 1383.8 |
| 公式 | C63H118N18O14S |
| 序列 |
KRMKVAKNAQ (Modifications: Lys-1 = N-terminal Myr) |
| 储存 | Store at -20°C |
| CAS Number | 1423381-07-0 |
| PubChem ID | 90488880 |
| InChI Key | WOHZPGNQJGMOFO-KJNWLHRWSA-N |
| Smiles | [H]N([C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)C(=O)CCCCCCCCCCCCC |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
产品说明书 for Pep2m, myristoylated
参考文献 for Pep2m, myristoylated
参考文献是支持产品生物活性的出版物。
Nishimune et al (1998) NSF binding to GluR2 regulates synaptic transmission. Neuron 21 87 PMID: 9697854
Noel et al (1999) Surface expression of AMPA receptors in hippocampal neurons is regulated by an NSF-dependent mechanism. Neuron 23 365 PMID: 10399941
Luthi et al (1999) Hippocampal LTD expression involves a pool of AMPARs regulated by the NSF-GluR2 interaction. Neuron 24 389 PMID: 10571232
Luscher et al (1999) Role of AMPA receptor cycling in synaptic transmission and plasticity. Neuron 24 649 PMID: 10595516
Yao et al (2008) PKMz maintains late long-term potentiation by N-ethylmaleimide-sensitive factor/GluR2-dependent trafficking of postsynaptic AMPA receptors. J.Neurosci. 28 7820 PMID: 18667614
按产品操作查看相关产品
关键词: Pep2m, myristoylated, Pep2m, myristoylated supplier, Peptide, inhibitors, inhibits, GluR2, subunit, binding, NSF, N-ethylmaleimide-sensitive, fusion, protein, Reduces, AMPA, currents, Glutamate, Receptors, iGlur, Ionotropic, GluA2, myr-pep2m, 3801, Tocris Bioscience
Pep2m, myristoylated 的评论
目前没有该产品的评论。 Be the first to review Pep2m, myristoylated and earn rewards!
Have you used Pep2m, myristoylated?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Alzheimer's Disease Poster
Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.